Litcius/Paper detail

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

Paul G Richardson, Aurore Perrot, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Laure Malinge, Franck Dubin, Helgi van de Velde, Kenneth C Anderson

2022The Lancet Oncology115 citationsDOI

Topics & Concepts

PomalidomideMedicineDexamethasoneInternal medicineMultiple myelomaRefractory (planetary science)OncologyPhases of clinical researchMallinckrodtClinical trialLenalidomideMultiple Myeloma Research and TreatmentsUbiquitin and proteasome pathwaysProtein Degradation and Inhibitors
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study | Litcius